Skip to content

NAVA vs. CMV Crossover in Severe BPD

Pilot Cross-Over Trial of Neurally Adjusted Ventilatory Assist (NAVA) and Conventional Flow Triggered Mechanical Ventilation (CMV) in Severe Bronchopulmonary Dysplasia (sBPD)

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04821453
Enrollment
12
Registered
2021-03-29
Start date
2021-09-13
Completion date
2025-02-28
Last updated
2026-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchopulmonary Dysplasia, Neurally Adjusted Ventilatory Assist, Mechanical Ventilation

Keywords

BPD, Bronchopulmonary Dysplasia

Brief summary

This prospective, unblinded, pilot randomized cross-over trial of 2 modes of mechanical ventilation will compare measures of pulmonary mechanics, respiratory gas exchange, and patient comfort between conventional flow triggered mechanical ventilation and neurally adjusted ventilatory assist (NAVA) among 20 prematurely born infants and young children receiving invasive respiratory support for severe bronchopulmonary dysplasia (BPD).

Detailed description

Most research to date in neonatal lung disease has focused on bronchopulmonary dysplasia (BPD) prevention. As a result, insufficient investigation has been performed to define optimal respiratory management strategies for infants and young children with established BPD. Thus, there is no robust evidence base to guide ventilator management to promote lung disease recovery and support neurodevelopment in this population. Neurally adjusted ventilatory assist (NAVA) is an alternative to conventional flow triggered ventilation that has shown promise for improving respiratory gas exchange, patient-ventilator interaction, and work of breathing in preterm neonates. The safety and efficacy of NAVA in infants and young children with established, severe BPD is uncertain. This prospective, unblinded, pilot randomized cross-over trial of 2 modes of mechanical ventilation will compare measures of pulmonary mechanics, respiratory gas exchange, and patient comfort between conventional flow triggered mechanical ventilation and NAVA among 20 prematurely born infants and young children receiving invasive respiratory support for severe BPD.

Interventions

DEVICENAVA

NAVA mode of mechanical ventilation provide the trigger for a spontaneous breath from the diaphragmatic movement instead of diaphragm and allows the patient to control the dynamics of the breath generally set in CMV mode.

DEVICECMV

CMV mode of mechanical ventilation that provides a trigger for a spontaneous breath from the airway flow sensor with dynamics of the breath set as required by the mode

Sponsors

Children's Hospital of Philadelphia
Lead SponsorOTHER
Rhode Island Hospital
CollaboratorOTHER
Children's Miracle Network
CollaboratorOTHER
American Respiratory Care Foundation
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Prospective, unblinded, pilot randomized cross-over trial of 2 modes of mechanical ventilation

Eligibility

Sex/Gender
ALL
Age
No minimum to 24 Months
Healthy volunteers
No

Inclusion criteria

1. Gestational ages (GA) ≤ 32 weeks 2. Current age between 36 weeks postmenstrual age (PMA) and 2 years corrected age 3. Severe BPD \[as per National Institutes of Health (NIH) consensus definition\] diagnosed at 36 weeks postmenstrual age 4. Receiving invasive mechanical ventilation for ongoing lung disease 5. Not expected to be ready for extubation within 11 days following enrollment 6. Parental consent

Exclusion criteria

1. Severe congenital anomalies 2. Known diaphragmatic defect 3. Current treatment with high frequency mechanical ventilation 4. Do not resuscitate (DNR) Status or Futility of Care 5. \>10% leak around the artificial airway, 6. Treatment with neuromuscular blockade within 72 hours prior to enrollment 7. Acute respiratory instability defined as a ventilator rate increase \> 15 beats per minute (bpm), Positive end-expiratory pressure (PEEP) increase \> 2 cm/water (H2O), sustained FiO2 increase \> 20%, and/or prescribed increase in tidal volume \> 2 mL/kg within 24 hours prior to enrollment will be excluded.

Design outcomes

Primary

MeasureTime frameDescription
Oxygen Saturation (SpO2) Indexup to 5 days per study armThe Oxygenation Saturation Index (OSI) is a composite measure of the severity of hypoxic respiratory failure. It quantifies how much ventilatory support is required to achieve a given level of oxygen saturation. Lower OSI values indicate better oxygenation and better clinical status. Higher OSI values indicate worse oxygenation and more severe respiratory failure. Oxygen saturation index will be measured by assessing if invasive mechanical ventilation with NAVA compared to CMV improves respiratory gas exchange in patients receiving invasive respiratory support for BPD. This will be calculated as the mean, time-weighted daily oxygen saturation (SpO2) index (\[mean airway pressure x Fraction of inspired oxygen (FiO2)\]/SpO2).

Secondary

MeasureTime frameDescription
Sedation Medicationsup to 5 days per study armThe need for sedation medication will be assessed by comparing the needs for sedation by the total daily dose milligram/kilogram (mg/kg) of sedation medications on invasive mechanical ventilation with NAVA compared to CMV.
Stressup to 5 days per study armPatient stress will be assessed by collecting salivary swabs three times per day to measure cortisol levels. The daily average will be assessed and compared as a marker for patient stress on invasive mechanical ventilation with NAVA compared to CMV.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORErik Jensen, MD, MSCE

Children's Hospital of Philadelphia

Participant flow

Pre-assignment details

12 subjects were enrolled in the study and 9 completed the study.

Baseline characteristics

Characteristic
Age, Customized
Under 13 months of age
12 Participants
Birth Weight
>1000 g
1 Count of Participants
Birth Weight
300-1000 g
11 Count of Participants
Gestational Age at Birth
23-25 weeks
6 Count of Participants
Gestational Age at Birth
26-29 weeks
6 Count of Participants
Sex: Female, Male
Female
6 Participants
Sex: Female, Male
Male
6 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 120 / 12
other
Total, other adverse events
2 / 124 / 12
serious
Total, serious adverse events
0 / 120 / 12

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026